CB Oncology Partners (Details) - USD ($)	1 Months Ended	3 Months Ended
	Jun. 30, 2020	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2021	Sep. 02, 2017
Condensed Income Statement Information [Abstract]
Patient revenue		$ 0	$ 1,061,000
Net (loss) income		(495,000)	292,000	$ 292,000
USNC's equity in (loss) income		(133,000)	(139,000)
Condensed Balance Sheet Information [Abstract]
Current assets		1,705,000			$ 2,243,000
TOTAL ASSETS		3,180,000			3,688,000
Current liabilities		624,000			327,000
Deficit		2,533,000			3,327,000
TOTAL LIABILITIES AND EQUITY		3,180,000			3,688,000
CB Oncology Partners LLC [Member]
Condensed Income Statement Information [Abstract]
Patient revenue		582,000	471,000
Net (loss) income		(46,000)	62,000
Condensed Balance Sheet Information [Abstract]
Current assets		582,000			400,000
Noncurrent assets		3,515,000			3,667,000
TOTAL ASSETS		4,097,000			4,067,000
Current liabilities		3,533,000			3,472,000
Noncurrent liabilities		3,125,000			3,121,000
Deficit		(2,561,000)			(2,526,000)
TOTAL LIABILITIES AND EQUITY		4,097,000			4,067,000
CB Oncology Partners LLC [Member]
CB Oncology Partners [Abstract]
Ownership percentage	28.58%					24.00%
Capital called from members	$ 500,000
Advances converted into equity	121,000
Contribution in cash	$ 212,000
Outstanding amount		2,208,000			2,174,000
Outstanding amount, less allowances		1,289,000			1,251,000
Due from related parties		$ 919,000			923,000
Note bearing interest		6.00%
Interest earned from the amounts owed by entity		$ 29,000	31,000
Accrued interest		427,000			$ 398,000
Condensed Income Statement Information [Abstract]
USNC's equity in (loss) income		$ (13,000)	$ 18,000